Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.

abstract：:A second meeting on reduced intensity allogeneic stem cell transplants (RI-HSCT) was convened in Zurich in February 2001 and focused on transplant-related mortality (TRM) and graft-versus-host disease (GVHD). Retrospective and prospective studies from the EBMT, national groups and single institutions included over 900...

journal_title：Bone marrow transplantation

authors： Bacigalupo A

更新日期：2002-02-01 00:00:00

abstract：:We report the experience of 14 centers which have used the combination of cytosine arabinoside (ara-C; 24-36 g/m2) and total body irradiation (TBI) to prepare 213 patients with acute lymphoblastic leukemia (ALL) for allogeneic BMT. The overall 3-year disease-free survival (DFS) probability is 38% (95% CI: 31-45%); 75 ...

journal_title：Bone marrow transplantation

authors： Weyman C,Graham-Pole J,Emerson S,August C,Champlin R,Coccia P,Fay J,Harris R,Koch P,Johnson L

更新日期：1993-01-01 00:00:00

abstract：:Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue has been evaluated in the treatment of children and young adults with brain tumors for whom conventional therapy is either too toxic (for example, radiotherapy in infants) or ineffective (for example, recurrent malignant tumors). With this...

journal_title：Bone marrow transplantation

authors： Marachelian A,Butturini A,Finlay J

更新日期：2008-01-01 00:00:00

abstract：:At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a ch...

journal_title：Bone marrow transplantation

authors： Cacchione A,LeMaitre A,Couanet DV,Benhamou E,Amoroso L,Simonnard N,Hartmann O

更新日期：2008-10-01 00:00:00

abstract：:Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

journal_title：Bone marrow transplantation

authors： Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

更新日期：2020-10-01 00:00:00

abstract：:A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell non-depleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse. Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due to logisti...

journal_title：Bone marrow transplantation

authors： Singhal S,Powles R,Treleaven J,Mehta J

更新日期：1997-06-01 00:00:00

abstract：:To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor...

journal_title：Bone marrow transplantation

authors： Hahn M,Böttcher S,Dietrich S,Hegenbart U,Rieger M,Stadtherr P,Bondong A,Schulz R,Ritgen M,Schmitt T,Tran TH,Görner M,Herth I,Luft T,Schönland S,Witzens-Harig M,Zenz T,Kneba M,Ho AD,Dreger P

更新日期：2015-10-01 00:00:00

abstract：:The kinetics of mobilization and optimal timing of peripheral blood progenitor cell (PBPC) collection were evaluated in 190 patients with multiple myeloma undergoing stem cell harvest after mobilization with cyclophosphamide, prednisone and G-CSF. There was a strong correlation between the WBC count and the number of ...

journal_title：Bone marrow transplantation

authors： Krieger MS,Schiller G,Berenson JR,Stewart K,Noga SJ,Ballester O,Tarantolo S,Stiff P,Kuhn D,Scherzo E,Sing A,Jacobs C,White JM,DiPersio J

更新日期：1999-07-01 00:00:00

abstract：:We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

journal_title：Bone marrow transplantation

authors： Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

更新日期：2014-02-01 00:00:00

abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

journal_title：Bone marrow transplantation

authors： Moffet JR,Mahadeo KM,McArthur J,Hsing DD,Gertz SJ,Smith LS,Loomis A,Fitzgerald JC,Nitu ME,Duncan CN,Hall MW,Pinos EL,Tamburro RF,Simmons RA,Troy J,Cheifetz IM,Rowan CM,Investigators of the Pediatric Acute Lung Injury an

更新日期：2020-02-01 00:00:00

abstract：:Bloodstream infection (BSI) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-SCT). Corticosteroids mask inflammatory responses, delaying the initiation of antibiotics. We reviewed medical records of 69 allo-SCT patients who had been on >0.5 mg/kg prednisolone to investig...

journal_title：Bone marrow transplantation

authors： Chizuka A,Kami M,Kanda Y,Murashige N,Kishi Y,Hamaki T,Kim SW,Hori A,Kojima R,Mori SI,Tanosaki R,Gomi H,Takaue Y

更新日期：2005-03-01 00:00:00

abstract：:Over the past 15 years, SCT has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). Mechanistic studies recently provided the proof-of-concept that restoration of immunological tolerance can be achieved by haematopoietic SCT in chronic autoimmunity through eradication of the pat...

journal_title：Bone marrow transplantation

authors： Alexander T,Bondanza A,Muraro PA,Greco R,Saccardi R,Daikeler T,Kazmi M,Hawkey C,Simoes BP,Leblanc K,Fibbe WE,Moore J,Snarski E,Martin T,Hiepe F,Velardi A,Toubert A,Snowden JA,Farge D

更新日期：2015-02-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro...

journal_title：Bone marrow transplantation

authors： Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X

更新日期：2010-08-01 00:00:00

abstract：:POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a plasma cell dyscrasia that differs substantially from classic multiple myeloma. It is often associated with disabling polyneuropathy in younger patients. Current therapeutic approaches are frequently inadequate ...

journal_title：Bone marrow transplantation

authors： Hogan WJ,Lacy MQ,Wiseman GA,Fealey RD,Dispenzieri A,Gertz MA

更新日期：2001-08-01 00:00:00

abstract：:Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT). Cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related...

journal_title：Bone marrow transplantation

authors： Gori E,Arpinati M,Bonifazi F,Errico A,Mega A,Alberani F,Sabbi V,Costazza G,Leanza S,Borrelli C,Berni M,Feraut C,Polato E,Altieri MC,Pirola E,Loddo MC,Banfi M,Barzetti L,Calza S,Brignoli C,Bandini G,De Vivo A,B

更新日期：2007-03-01 00:00:00

abstract：:Filgrastim (r-metHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) and unstimulated bone marrow (BM) were evaluated and compared for reconstitution after high-dose chemotherapy in patients with relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) with respect to engraftment, overall and relapse-fr...

journal_title：Bone marrow transplantation

authors： Kanteti R,Miller K,McCann J,Roitman D,Morelli J,Hurley C,Berkman E,Schenkein D

更新日期：1999-09-01 00:00:00

abstract：:This was an open-label, single-center, phase II study of 20 patients with multiple myeloma who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT. The aim was to assess the safety and efficacy of plerixafor for stem cell mob...

journal_title：Bone marrow transplantation

authors： Tricot G,Cottler-Fox MH,Calandra G

更新日期：2010-01-01 00:00:00

abstract：:Fentanyl is a synthetic opioid that can be delivered through a transdermal therapeutic system (TTS). The aim of this study was to assess the efficacy of fentanyl TTS in treating oral mucositis pain in 75 adult hematopoietic stem cell transplant (HSCT) patients. The analysis was based on 62 patients who developed mucos...

journal_title：Bone marrow transplantation

authors： Demarosi F,Lodi G,Soligo D,Sardella A,Volpe AD,Carrassi A,Deliliers GL

更新日期：2004-06-01 00:00:00

abstract：:The purpose of this study was to evaluate if the tumor load, as determined by a real-time quantitative PCR (RQ-PCR) assay, correlated with the clinical course of follicular lymphoma patients after stem cell transplantation (SCT). Cryopreserved bone marrow and/or peripheral blood samples obtained at different time inte...

journal_title：Bone marrow transplantation

authors： Chang CC,Bredeson C,Juckett M,Logan B,Keever-Taylor CA

更新日期：2003-08-01 00:00:00

abstract：:Four patients with acute myeloid leukaemia relapsed within 6 months of allogeneic BMT. Three patients were treated with cytosine arabinoside and amsacrine while the fourth received no chemotherapy. All patients received infusions of leucocytes obtained by repeated leukapheresis from the original bone marrow donor. Thr...

journal_title：Bone marrow transplantation

authors： Szer J,Grigg AP,Phillips GL,Sheridan WP

更新日期：1993-02-01 00:00:00

abstract：:The role of allogeneic hematopoietic SCT (allo-HCT) in multiple myeloma (MM) remains controversial. A total of 58 patients received an allo-HCT (25 of them with myeloablative conditioning-allo-MAC-and 33 with reduced-intensity conditioning-allo-RIC) at our institution over a 28-year period. The CR rate for allo-MAC wa...

journal_title：Bone marrow transplantation

authors： Rosiñol L,Jiménez R,Rovira M,Martínez C,Fernández-Avilés F,Marín P,Suárez-Lledó M,Gutiérrez-García G,Fernández de Larrea C,Carreras E,Urbano-Ispizua A,Bladé J

更新日期：2015-05-01 00:00:00

abstract：:Six children with clinical and hematologic features of juvenile chronic myelogenous leukemia (JCML) underwent bone marrow transplantation (BMT) using T cell-depleted marrow from non-HLA-matched related or closely HLA-matched unrelated donors. Patient ages ranged from 1.2 to 5 years. Four patients received cytoreductiv...

journal_title：Bone marrow transplantation

authors： Bunin NJ,Casper JT,Lawton C,Murray K,Camitta BM,Greenwood M,Geil J,Ash RC

更新日期：1992-02-01 00:00:00

abstract：:In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 m...

journal_title：Bone marrow transplantation

authors： Nasilowska-Adamska B,Rzepecki P,Manko J,Czyz A,Markiewicz M,Federowicz I,Tomaszewska A,Piatkowska-Jakubas B,Wrzesien-Kus A,Bieniaszewska M,Duda D,Szydlo R,Halaburda K,Szczepinski A,Lange A,Hellman A,Robak T,Skotnicki A

更新日期：2007-11-01 00:00:00

abstract：:We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

更新日期：2008-03-01 00:00:00

abstract：:Syngeneic BMT was first performed successfully in China in 1964. In 1981, allogeneic BMT was applied in an acute leukemia patient with success. Since then, the number of BMTs has been increasing gradually, especially since the 1990s. More than 2000 stem cell transplants per year have been performed in recent years in ...

journal_title：Bone marrow transplantation

authors： Wu T,Lu DP

更新日期：2008-08-01 00:00:00

abstract：:Allogeneic BMT for patients with acute myeloid leukemia (AML) is presently a reference therapy. The indications for this therapy mainly rely upon prognostic factors, and their importance is constantly reassessed. To examine the impact of time from diagnosis to transplant on survival and leukemia-free survival (LFS), w...

journal_title：Bone marrow transplantation

authors： Jourdan E,Maraninchi D,Reiffers J,Gluckman E,Rio B,Jouet JP,Michallet M,Molina L,Archimbaud E,Harousseau JL,Ifrah N,Attal M,Guilhot F,Kuentz M,Guyotat D,Pico JL,Dauriac C,Legros M,Dreyfus F,Bordigoni P,Leblond V,

更新日期：1997-05-01 00:00:00

abstract：:Autologous stem cell transplantation (PBSCT) is standard for young patients in MM and its TRM has decreased after the 2000s. Bortezomib and immunomodulatory agents (IMiDs) in MM have improved the outcome. However, they seem to boost pro-inflammatory stage increasing the incidence of engraftment syndrome (ES). Favorabl...

journal_title：Bone marrow transplantation

authors： Gutiérrez-García G,Rovira M,Magnano L,Rosiñol L,Bataller A,Suárez-Lledó M,Cibeira MT,de Larrea CF,Garrote M,Jorge S,Moreno A,Rodríguez-Lobato LG,Carreras E,Díaz-Ricart M,Palomo M,Martínez C,Urbano-Ispizua A,Bladé J,Fe

更新日期：2018-12-01 00:00:00

abstract：:Ninety-eight patients with homozygous-beta thalassemia who had undergone allogeneic bone marrow transplantation (BMT) between May 1990 and March 1992 were tested for hepatitis C antibodies (anti-HCV) before and after BMT. Anti-HCV positivity was detected in 50 of the 98 patients (51%) before BMT. Seroconversion was de...

journal_title：Bone marrow transplantation

authors： Erer B,Angelucci E,Lucarelli G,Giardini C,Baronciani D,Galimberti M,Polchi P,Amadei G,Battistini L,Paolucci S

更新日期：1994-09-01 00:00:00

abstract：:Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

journal_title：Bone marrow transplantation

authors： Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

更新日期：2019-11-01 00:00:00

abstract：:Peg-filgrastim is a form of G-CSF with a sustained duration of action due to self-limited clearance. We administered 6 mg peg-filgrastim to 18 autograft recipients on day +1 after transplantation for hematologic malignancies. Plasma samples were collected at baseline and during transplantation. Hematopoietic recovery ...

journal_title：Bone marrow transplantation

authors： Piccirillo N,De Matteis S,De Vita S,Laurenti L,Chiusolo P,Sorà F,Reddiconto G,d'Onofrio G,Leone G,Sica S

更新日期：2007-09-01 00:00:00